Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Giuseppe Aimo is active.

Publication


Featured researches published by Giuseppe Aimo.


Gut | 2001

Duration of gluten exposure in adult coeliac disease does not correlate with the risk for autoimmune disorders

C Sategna Guidetti; E Solerio; Nadia Scaglione; Giuseppe Aimo; Giulio Mengozzi

BACKGROUND AND AIMS Duration of gluten exposure seems to predispose adolescents with coeliac disease to autoimmune diseases. In a retrospective cohort study, we assessed the relationship between autoimmune disorders and actual gluten exposure in patients in whom coeliac disease was diagnosed in adult life (⩾16 years). METHODS We screened for the presence of autoimmunity in 605 controls (16–84 years) and 422 patients (16–84 years), all of whom had been on gluten withdrawal for at least one year (median follow up 9.5 years). A logistic regression analysis, setting the prevalence of autoimmunity as the dependent variable, was employed to control for independent covariates as predictors of the risk of autoimmunity. RESULTS The prevalence of autoimmunity was threefold higher (p<0.00001) in patients than in controls. Mean duration of gluten exposure was 31.2 and 32.6 years for patients with or without autoimmunity. Logistic regression showed that increased age at diagnosis of coeliac disease was related to the prevalence of autoimmune disease while “actual gluten exposure” which takes into account diet compliance, follow up, and age at diagnosis of autoimmune disorders were not predictive for the risk of developing autoimmune diseases (odds ratio 0.82 per year). CONCLUSION The prevalence of autoimmune diseases in patients with a late coeliac disease diagnosis does not correlate with duration of gluten intake. Early exposure to gluten may modify the immunological response. Gluten withdrawal does not protect patients with a late diagnosis from autoimmune diseases.


Cell Biochemistry and Function | 2010

Pluripotent plasticity of stem cells and liver repopulation

Luisa Gennero; Maria Augusta Roos; Kirk Sperber; Tetyana Denysenko; Paola Bernabei; Gian Franco Calisti; Mauro Papotti; Susanna Cappia; Roberto Pagni; Giuseppe Aimo; Giulio Mengozzi; G. P. Cavallo; Stefano Reguzzi; Gian Piero Pescarmona; Antonio Ponzetto

Different types of stem cells have a role in liver regeneration or fibrous repair during and after several liver diseases. Otherwise, the origin of hepatic and/or extra‐hepatic stem cells in reactive liver repopulation is under controversy. The ability of the human body to self‐repair and replace the cells and tissues of some organs is often evident. It has been estimated that complete renewal of liver tissue takes place in about a year. Replacement of lost liver tissues is accomplished by proliferation of mature hepatocytes, hepatic oval stem cells differentiation, and sinusoidal cells as support. Hepatic oval cells display a distinct phenotype and have been shown to be a bipotential progenitor of two types of epithelial cells found in the liver, hepatocytes, and bile ductular cells. In gastroenterology and hepatology, the first attempts to translate stem cell basic research into novel therapeutic strategies have been made for the treatment of several disorders, such as inflammatory bowel diseases, diabetes mellitus, celiachy, and acute or chronic hepatopaties. In the future, pluripotent plasticity of stem cells will open a variety of clinical application strategies for the treatment of tissue injuries, degenerated organs. The promise of liver stem cells lie in their potential to provide a continuous and readily available source of liver cells that can be used for gene therapy, cell transplant, bio‐artificial liver‐assisted devices, drug toxicology testing, and use as an in vitro model to understand the developmental biology of the liver. Copyright


Journal of Endocrinological Investigation | 2000

Bone turnover in hyperthyroidism before and after thyrostatic management

Giancarlo Isaia; Cristiana Roggia; D. Gola; M. Di Stefano; G. Gallone; Giuseppe Aimo; P. Ardissone; M. Mussetta

Hyperthyroidism is associated with enhanced osteoblastic and osteoclastic activity, and patients frequently have low bone mineral density and high bone turnover. The aim of this study was to examine the bone formation and resorption markers trend in 12 female patients, before and after normalization of thyroid activity. The following measurements were made at baseline and 1 and 6 months after hormone normalization induced by methimazole treatment: total alkaline phosphatase (ALP), bone alkaline phosphatase (BALP), collagen type C-terminal propeptide (PICP), osteocalcin (BGP), telopeptide (ICTP), urinary-hydroxyproline/ urinary creatinine (uOHP/uCreat), urinary calcium/urinary creatinine (uCa/uCreat) and deoxypyridinoline crosslinks (D-Pyr). Compared with controls, all of these parameters were significantly increased (ALP p=0.014; BALP p=0.0001; PICP p=0.013; BGP p=0.009; ICTP p=0.0001; uOHP/uCreat p=0.002; uCa/uCreat p=0.044; crosslinks p=0.0001). After treatment the values of ALP, BALP and PICP in hyperthyroid patients showed an initial slight increase and then a significant downwards trend (ALP p=0.008, BAP p= 0.001, PICP p=0.026). Furthermore, resorption markers showed a significant decrease (uOHP/ uCreat p<0.005 and D-Pyr p<0.008). As regards lumbar BMD patients, measurements were significantly reduced in comparison with the control group (p=0.005). Six months after serum thyroid hormones level normalization, we observed a significant increase (p=0.014 vs baseline). Both neo-formation and resorption markers are useful to assess pathological bone turnover and bone involvement in hyperthyroidism. They could also be employed to monitor the effect of antithyroid treatment on bone and to indicate if bone antiresorption therapy should be considered.


Tumori | 1996

PRELIMINARY RESULTS OF CLINICAL EVALUATION OF THE FREE/TOTAL PROSTATE-SPECIFIC ANTIGEN RATIO IN A MULTICENTRIC STUDY

Riccardo Mione; Giuseppe Aimo; Emilio Bombardieri; Alberto Cianetti; Mario Correale; Paola Barioli; Mario Barichello; Carlo Terrone; Simonetta Massaron; Seregni E; Domenico Marzano; Ines Abbate; Antonio Pagliarulo; Massimo Gion

Aims and Background The free/total (F/T) prostate-specific antigen (PSA) ratio is probably the most promising tool proposed to increase the specificity of PSA in the diagnosis of prostate cancer. The aim of the present study was to evaluate the clinical value of the F/T ratio in 138 patients with benign hyperplasia, 101 with untreated prostate cancer, and 176 apparently healthy men. Methods We used a new immunometric assay of free PSA (FPSA-RIACT, CIS Diagnostici, Italy) which has shown good analytical performance; sample handling and storage under routine conditions did not affect the antigen stability. Results The diagnostic efficiency of the F/T ratio was significantly better than that of total PSA. In patients with total PSA ranging from 4 to 10 ng/ml, at a specificity level of 95% total PSA showed a sensitivity of 7%, whereas the sensitivity of F/T increased to 70%. Using the F/T ratio as a decision tool in association with total PSA and considering all cases candidate to biopsy (total PSA greater than 3.79 ng/ml corresponding to the 95% level), we demonstrated a 35% reduction of total biopsies that would have been required on the basis of total PSA alone. Conclusions The determination of the percentage of F/T serum PSA significantly improves the specificity of the marker, particularly in the 4-10 ng/ml dose range where unnecessary prostate biopsies can be reduced.


Nephron | 1992

Immunologic Characteristics of Fibrillary Glomerulonephritis

Cristiana Rollino; Dario Roccatell; Gianna Mazzucco; Mario Boccadoro; Massimo Massaia; Silvano Battaglio; Paola Omedè; A. Amoroso; Gina Mazzola; Giuseppe Aimo; Rosanna Coppo; Giuseppe Piccoli

IgG and IgA immune complexes, mononuclear phagocytic system function, interleukin-2 (IL-2) production by peripheral blood lymphocytes (PBL), serum-soluble IL-2 receptors, tumor necrosis factor, beta 2-microglobulin and IL-1 beta, HLA-DNA polymorphisms, immuno-isoelectrofocusing, phenotype of PBL, lymphocyte cytotoxicity, activation of lymphokine-activated killer cells and natural killer cell activity were evaluated in 8 patients with tubular/fibrillary glomerulonephritis (GN). No common serologic, immunologic or immunogenetic features suggestive of plasma cell dyscrasias were found. No elements to state whether these GNs represent a new entity or just atypical forms of known GN were found.


American Journal of Nephrology | 1993

Soluble interleukin-2 receptors and beta 2-microglobulin in patients with primary glomerulonephritis.

Cristiana Rollino; Dario Roccatello; Maria Claudia Amprimo; Guido Cavalli; Giuseppe Aimo; Giulietta Beltrame; Bruno Basolo; Guido Martina; Giuseppe Piccoli

Serum levels of soluble interleukin-2 receptors (IL2R) and of beta 2-microglobulin (beta 2M) were studied with the immunoenzymatic technique in 38 patients with primary glomerulonephritis (GN), in 10 patients with essential hypertension (EH) and in 30 healthy subjects. IL2R correlated with beta 2M (p < 0.05). IL2R and beta 2M were higher in patients with GN (p < 0.003, p < 0.001, respectively) and in patients with EH (p < 0.003, p < 0.01, respectively) than in healthy subjects. IL2R and beta 2M correlated with serum creatinine, but not with proteinuria. Our data would suggest the existence of lymphocyte activation in patients with GN. Only speculations can be advanced with regard to the observed increase in these parameters in EH patients.


Clinical Chemistry | 2002

Comparative Evaluation of Serologic Tests for Celiac Disease Diagnosis and Follow-Up

Silvia Martini; Giulio Mengozzi; Giuseppe Aimo; Laura Giorda; Roberto Pagni; Carla Sategna Guidetti


Clinical Chemistry | 2001

Diagnostic Accuracies for Celiac Disease of Four Tissue Transglutaminase Autoantibody Tests Using Human Antigen

Silvia Martini; Giulio Mengozzi; Giuseppe Aimo; Roberto Pagni; Carla Sategna-Guidetti


Clinical Chemistry | 1998

Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions

Massimo Gion; Riccardo Mione; Paola Barioli; Mario Barichello; Filiberto Zattoni; Tommaso Prayer-Galetti; Mario Plebani; Giuseppe Aimo; Carlo Terrone; Fabio Manferrari; Giuseppe Madeddu; Livio Caberlotto; Andrea Fandella; C. Pianon; Luisa Vianello


Artificial Organs | 2008

Serum and Intracellular Detection of Cytokines in Patients Undergoing Chronic Hemodialysis

Dario Roccatello; Marco Formica; Guido Cavalli; Giacomo Quattrocchio; Giuseppe Aimo; Renato Polloni; Maria Claudia Amprimo; Andrea Moho; Guido Martha; Ciro Isidoro; Maurizia Mazengo; Rosanna Coppo; Luigi M. Sena; Giuseppe Piccoli

Collaboration


Dive into the Giuseppe Aimo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Carlo Terrone

University of Eastern Piedmont

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge